Wang 2008b.

Methods	Allocation: randomised. Blindness: not reported. Duration: 6 weeks (2007‐2008). Setting: Shandong Center for Mental Health, Jinan, China.
Participants	Diagnosis: schizophrenia DSM‐IV. N = 60. Age: Olanzapine: 33.1±7.6 years; perphenazine: 31.2±3.2 years. Sex: F26, M34 (Olanzapine F12, M18; perphenazine F14, M16). History: length of illness olanzapine: 78.5 ± 6.8 months; perphenazine: 79.6 ± 9.5 months. Included: schizophrenia combined with positive symptoms; PANSS≥ 70, Positive score ≥ 25. Exclusion: not reported. Consent: not stated.
Interventions	1. Perphenazine: start from 8 mg/day, maximum dosage: 60 mg/day, n =30. 2. Olanzapine (Changzhou Watson Pharmacy Ltd.): start from 5 mg/day, maximum dosage: 20 mg/day, n = 30.
Outcomes	PANSS score. TESS score. Clinical prognosis assessment: decreased rate of PANSS score = (pre‐treatment score‐post‐treatment score)/pre‐treatment score ≥ 75%‐‐recovery; 50%‐ to ‐74% markedly improved; 25% to 49% improved; < 25% no effect.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised – no further details.
Allocation concealment (selection bias)	Unclear risk	Not stated.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not stated.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No description.
Selective reporting (reporting bias)	Low risk	None detected.
Other bias	Unclear risk	Funding: not stated. Rating scales: raters not stated to be independent of treatment.